This groundbreaking piece from the HESI Cardiac Safety Committee proposes a new alternative approach to preclinical drug safety assessment, using human cell-based models and computational methods to identify human-relevant liabilities earlier in the process.
Challenging the status quo: a framework for mechanistic and human-relevant cardiovascular safety screening. Berridge et al., March 2024. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2024.1352783
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.